Today’s cyclodextrin:
ZyVersa Therapeutics Inc.‘ Cholesterol Efflux Mediator VAR 200 (HPBCD) will be dosed in patients with diabetic kidney disease in Q2 2025.
The first patient is expected to be treated in a phase 2a clinical trial in patients with DKD by the end of June of 2025. The intent of the study is to obtain renal patient proof-of-concept for VAR 200 prior to initiating a larger phase 2a/b for VAR 200’s lead indication, FSGS. The DKD study will evaluate VAR 200’s safety and efficacy (% change in proteinuria from baseline to week 12) in eight patients with type 2 diabetes who have diabetic kidney disease. This data will provide insights for designing the subsequent phase 2a/b FSGS study. The DKD study will be conducted at two clinical research sites.
I cannot wait to see how this goes!
ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress :: ZyVersa Therapeutics, Inc.
